LIFEBIT BIOTECH LIMITED

Latest accounts filed cover 2024-12-31; financial figures currently reflect up to 2022-12-31.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

RSM UK Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“At the time of approving the financial statements the directors have a reasonable expectation that the group and company has adequate resources to continue in operational existence for the foreseeable future. The directors have prepared forecast information that indicates that the cash balances available will provide a cash runway for a period of at least 12 months from the date of approval of the financial statements. The directors therefore continue to adopt the going concern basis of accounting in preparing the financial statements.”

Group structure

1. LIFEBIT BIOTECH LIMITED · parent
   1. Lifebit Biotech (Spain), S.L. 100% · Spain · provision of local customer support and development services to the parent company.
   2. Lifebit Biotech Greece Single Member Private Company 100% · Greece · provision of local customer support and development services to the parent company.
   3. Lifebit Biotech PTE. Ltd 100% · Singapore · provision of local customer support and development services to the parent company.
   4. Lifebit Biotech Inc. 100% · USA · provision of local customer support and development services to the parent company.
   5. Lifebit Biotech Australia Pty Ltd 100% · Australia · provision of local customer support and development services to the parent company.

Significant events

• “During the year ended December 2024 the group's annual turnover increased from £4.613m to £5.176m. The growth in revenues was driven by a combination of new customer acquisition, continued renewals, upsells, and new revenue streams from additional platform functionalities launched in 2024.”
• “Gross profit increased from £3.121m to £3.904m, with gross margin increasing from 68% to 75% due to increased operational efficiency.”
• “Administrative expenses, excluding the exceptional expense of £0.879m, at £13.114m were 20% lower than prior year as the company delivered on a cost optimisation programme.”
• “Overall, the group made an operating loss before exceptional expense of £9.209m (2023: £13.289m). Loss before taxation is £8.622m (2023: £14.406m).”
• “During 2024, the group's cash position decreased from £30.532m to £23.624m, a reflection of the continued investment in product development, sales, security, and compliance.”
• “No ordinary dividends were paid during the year, and the directors do not recommend payment of a final dividend.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

1

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  -8.8%

  £48,151,134 → £43,931,279

• Net assets

  -9.1%

  £48,234,504 → £43,858,748

• Employees

  0%

  39 → 39

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers